MA27837A1 - Beta-carbolines utiles pour traiter une maladie inflammatoire. - Google Patents

Beta-carbolines utiles pour traiter une maladie inflammatoire.

Info

Publication number
MA27837A1
MA27837A1 MA28592A MA28592A MA27837A1 MA 27837 A1 MA27837 A1 MA 27837A1 MA 28592 A MA28592 A MA 28592A MA 28592 A MA28592 A MA 28592A MA 27837 A1 MA27837 A1 MA 27837A1
Authority
MA
Morocco
Prior art keywords
inflammatory disease
treating inflammatory
useful
beta carbolines
beta
Prior art date
Application number
MA28592A
Other languages
English (en)
Inventor
Michael E Hepperle
Julie Fields Liu
Francois Soucy
Yingchun Ye
Robert S Murray
Raman Prakash
Jeremy D Little
Alfredo Castro
Hormoz Mazdiyasni
Paul E Fleming
Dominic Reynolds
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA27837A1 publication Critical patent/MA27837A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA28592A 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire. MA27837A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46146803P 2003-04-09 2003-04-09

Publications (1)

Publication Number Publication Date
MA27837A1 true MA27837A1 (fr) 2006-04-03

Family

ID=33299818

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28592A MA27837A1 (fr) 2003-04-09 2005-11-09 Beta-carbolines utiles pour traiter une maladie inflammatoire.

Country Status (22)

Country Link
US (2) US7727985B2 (fr)
EP (1) EP1611134A1 (fr)
JP (1) JP2006522824A (fr)
KR (1) KR20060006031A (fr)
CN (1) CN1802375A (fr)
AU (1) AU2004230952A1 (fr)
BR (1) BRPI0409263A (fr)
CA (1) CA2521300A1 (fr)
CO (1) CO5700746A2 (fr)
CR (1) CR8042A (fr)
EA (1) EA009121B1 (fr)
EC (1) ECSP056145A (fr)
HR (1) HRP20050926A2 (fr)
MA (1) MA27837A1 (fr)
MX (1) MXPA05010793A (fr)
NI (1) NI200500174A (fr)
NO (1) NO20054598L (fr)
OA (1) OA13115A (fr)
RS (1) RS20050832A (fr)
TN (1) TNSN05257A1 (fr)
WO (1) WO2004092167A1 (fr)
ZA (1) ZA200508198B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA009121B1 (ru) 2003-04-09 2007-10-26 Миллениум Фармасьютикалз, Инк. Бета-карболины, применяемые для лечения воспалительных заболеваний
EP2206713A1 (fr) * 2004-04-09 2010-07-14 Millennium Pharmaceuticals, Inc. Béta-carbolines utiles pour traiter une maladie inflammatoire
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006316322B2 (en) * 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
CA2646316C (fr) 2006-03-15 2016-05-24 Theralogics, Inc. Methodes de traitement des maladies d'atrophie musculaire au moyen d'inhibiteurs de l'activation de nf-kb
WO2008002246A1 (fr) * 2006-06-28 2008-01-03 Astrazeneca Ab Composition pharmaceutique comprenant un inhibiteur de la ikk2 et un second ingrédient actif
CA2670730A1 (fr) * 2006-12-13 2008-06-26 Gilead Sciences, Inc. Monophosphates utilises comme promedicaments mutuels de modulateurs de la transduction du signal anti-inflammatoires et de beta-agonistes dans le traitement de l'inflammaton pulmonaire et de la bronchoconstriction
WO2009054965A1 (fr) * 2007-10-23 2009-04-30 Millennium Pharmaceuticals, Inc. Sel de n-(6-chloro-9h-pyrido[3,4-b]indol-8-yl)-4-[2-(2,6-diméthyl-4-morpholinyl)-2-oxoéthyl]-6,6-diméthylmorpholinecarboxamide
US20090137579A1 (en) * 2007-10-23 2009-05-28 Millennium Pharmaceuticals, Inc. Mesylate salt of an IKK inhibitor
EP2297347B1 (fr) 2008-05-14 2017-03-08 Millennium Pharmaceuticals, Inc. Méthodes et trousses pour surveiller les effets d'immunomodulateurs sur l'immunité adaptative
JP5312466B2 (ja) 2008-10-02 2013-10-09 旭化成ファーマ株式会社 ８位置換イソキノリン誘導体及びその用途
EP2552428A1 (fr) 2010-03-30 2013-02-06 Novartis AG Inhibiteurs de la protéine kinase c (pkc) pour le traitement d'un lymphome b à signalisation active chronique des récepteurs des cellules b active chronique
DK2691394T3 (en) * 2011-03-28 2017-08-28 Sjt Molecular Res S L RELATIONSHIPS FOR TREATMENT OF METABOLIC SYNDROME
CN102416014B (zh) * 2011-09-13 2012-11-21 河南中医学院 一种生物碱类成分组合物在制备抗甲型h1n1流感病毒药物中的应用
CN102391323B (zh) * 2011-10-18 2013-09-25 首都医科大学 四氢-β-咔啉衍生物、其制备方法及其用途
KR101646916B1 (ko) 2015-07-13 2016-08-09 강원대학교산학협력단 베타-카르볼린 알칼로이드 화합물을 함유하는 염증성 질환의 예방 또는 치료용 조성물
WO2017067670A1 (fr) 2015-10-23 2017-04-27 Pharmathen S.A. Nouveau procédé de préparation de tryptamines et de leurs dérivés
CN109593089B (zh) * 2019-01-24 2022-01-28 西南大学 二氮杂螺癸烷哌啶甲酰胺类化合物制备和应用
CN112824387B (zh) * 2019-11-21 2023-03-21 济南尚博生物科技有限公司 一种2-甲基烟酸酯及其制备方法和应用
CN117510494B (zh) * 2023-11-07 2024-04-19 桂林医学院附属医院 β-咔啉-沙利度胺偶联物及其在制备逆转ABT-199耐药的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2242402T3 (es) * 1998-08-12 2005-11-01 Pfizer Products Inc. Inhibidores de tace.
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001068648A1 (fr) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Beta-carbolines substituees ayant une activite inhibitrice de l'ikb-kinase
AU3741801A (en) 2000-03-15 2001-09-24 Aventis Pharma Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
DE60220422T2 (de) * 2001-09-19 2008-02-07 Pharmacia Corp. Substituierte pyrazol-verbindungen zur behandlung von entzündungen
US9248124B2 (en) * 2001-11-07 2016-02-02 Millennium Pharmaceuticals, Inc. Use of inhibitors of IκB kinase for the treatment of cancer
CN1753884A (zh) * 2003-03-07 2006-03-29 伊莱利利公司 阿片类受体拮抗剂
EA009121B1 (ru) 2003-04-09 2007-10-26 Миллениум Фармасьютикалз, Инк. Бета-карболины, применяемые для лечения воспалительных заболеваний

Also Published As

Publication number Publication date
CN1802375A (zh) 2006-07-12
WO2004092167A8 (fr) 2006-01-05
NI200500174A (es) 2006-04-17
ECSP056145A (es) 2006-04-19
EP1611134A1 (fr) 2006-01-04
KR20060006031A (ko) 2006-01-18
EA009121B1 (ru) 2007-10-26
HRP20050926A2 (en) 2006-06-30
MXPA05010793A (es) 2005-12-05
OA13115A (en) 2006-11-10
EA200501584A1 (ru) 2006-06-30
NO20054598D0 (no) 2005-10-06
ZA200508198B (en) 2007-01-31
US7727985B2 (en) 2010-06-01
AU2004230952A1 (en) 2004-10-28
WO2004092167A1 (fr) 2004-10-28
US20100093713A1 (en) 2010-04-15
CO5700746A2 (es) 2006-11-30
CR8042A (es) 2006-05-30
BRPI0409263A (pt) 2006-03-28
CA2521300A1 (fr) 2004-10-28
RS20050832A (en) 2007-12-31
US20040235839A1 (en) 2004-11-25
NO20054598L (no) 2005-10-27
JP2006522824A (ja) 2006-10-05
TNSN05257A1 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
MA27837A1 (fr) Beta-carbolines utiles pour traiter une maladie inflammatoire.
NL1028310A1 (nl) Benzopyranverbindingen toepasbaar voor het behandelen van ontstekingsaandoeningen.
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
IL185422A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
DE602004019373D1 (de) Bilderzeugungsverfahren
IL178328A0 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
DE602005010597D1 (de) Bildaufzeichnungsverfahren
DE602004008773D1 (de) 2-(6-amino-pyridin-3-yl)-2-hydroxyethylamin-verbindungen als beta 2-adrenoceptoren agonisten
HK1098155A1 (en) Nicotinic receptor agonists for the treatment of inflammatory diseases
ITRE20030089A1 (it) Gruppo autocentrante perfezionato.
LU91032B1 (de) Mauerstein.
FR2883559B1 (fr) Cric electromecanique pour vehicules.
FR2858344B1 (fr) Bloc pour paroi bio climatique.
FI20030467A0 (fi) Menetelmä tulehdustilojen hoitamiseen
FR2858212B1 (fr) Cercueil en particulier pour la cremation
EP1667677A4 (fr) Composition de traitement de la maladie intestinale inflammatoire
FR2858915B1 (fr) Rabatteur pour faucheusse-moissonneuse
ITTO20031040A1 (it) Gruppo cuscinetto mozzo-ruota per veicoli.
NO20033896D0 (no) Systemarkitektur optimert for skalerbarhet
ITTO20020279A1 (it) Complesso di raccordo per tratti di tubazioni.
ES1051316Y (es) Quiosco.
ITMI20031386A1 (it) Impianto di lavaggio per componenti meccanici.
ITMO20040266A1 (it) Apparato trasportatore.
ITTO20030955A1 (it) Gruppo mozzo-puleggia.
ITMO20030032A0 (it) Apparato per la finitura di getti di fusione.